The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2020
Filed:
May. 18, 2016
Applicants:
Daiichi Sankyo Europe Gmbh, Munich, DE;
Daiichi Sankyo Company Limited, Tokyo, JP;
Inventors:
Reimar Abraham, Munich, DE;
Mauricio Redondo-Müller, Germering, DE;
Assignees:
Daiichi Sankyo Europe GmbH, Munich, DE;
Daiichi Sankyo Company Limited, Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/07 (2006.01); A61K 31/122 (2006.01); A61K 31/355 (2006.01); A61K 31/785 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 31/59 (2006.01); A61K 31/787 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61P 21/00 (2006.01); A61P 9/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 13/12 (2006.01); A61P 35/00 (2006.01); A61K 31/395 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/07 (2013.01); A61K 31/122 (2013.01); A61K 31/355 (2013.01); A61K 31/395 (2013.01); A61K 31/59 (2013.01); A61K 31/785 (2013.01); A61K 31/787 (2013.01); A61K 38/179 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 13/12 (2018.01); A61P 21/00 (2018.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.